SOURCE: Goldman Small Cap Research, Inc.

September 13, 2013 09:30 ET

Establishing a Good Manufacturing Practices Facility Serves as a Catalyst for Nuvilex

BALTIMORE, MD--(Marketwired - Sep 13, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that one of the key catalysts in the near term for Nuvilex Inc. (OTCQB: NVLX) is the establishment of a GMP (Good Manufacturing Practices) facility. The facility will be used to encapsulate the live cells that are part of the Company's pancreatic cancer treatment necessary for future clinical trials. While on the surface it may appear that the GMP term is esoteric, the success of many firms in the health care sector depends upon it.

GMP involves a series of complex and specific documentation of production and testing procedures to ensure the production of quality products. Before a facility can be blessed with the GMP moniker, it is overseen and regulated by government agencies, such as the FDA in the United States. However, the key point is that a drug or device company may develop and pass all phases of the clinical trials for a new drug or technology but may not be able to produce it if conditions violate GMP.

Clearly, developing the manufacturing and testing processes and procedures to meet GMP is one of the critical next steps for the Company as the final clinical trial stages for its advanced pancreatic cancer treatment commence.

In establishing the GMP facility and standards for the production of the encapsulated cancer-drug-activating cells required for Nuvilex's future clinical trials in patients with advanced, inoperable pancreatic cancer, the in-house expertise within the Company may be coupled with that of experts from SG Austria, the company from whom the pancreatic cancer treatment was acquired. The latter are those who developed the treatment and who have already produced the encapsulated cancer-drug-activating live cells that are part of the overall treatment according to GMP standards.

By virtue of this unique relationship between Nuvilex and SG Austria, GMP production of the encapsulated cells that are part of Nuvilex's pancreatic cancer treatment should be significantly facilitated and expedited and the Company should avoid the pitfalls often experienced by biotech firms in producing their products according to GMP standards.

Completing the GMP facility construction and establishing GMP standards for production of the encapsulated cells that are part of its pancreatic cancer treatment should serve as a catalyst for the Company and bring Nuvilex one step closer to advanced clinical trials.

To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: www.nuvilex.com.

Contact Information